GeoVax Labs Inc
Filed Jun 16, 2025.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Jun 16, 2025
GOVX$0.16-0.1%Stored close · as of Nov 6, 2026
Contents
Clinical Development Programs
| Product | Indication | Clinical Trial | Status |
|---|---|---|---|
| Primary Vaccine for Immunocompromised/Stem Cell Transplant Patients (NCT04977024) | Phase 2 Currently enrolling | ||
| GEO-CM04S1 | COVID-19 | Booster Vaccine for Immunocompromised/Chronic Lymphocytic Leukemia Patients (NCT05672355) | Phase 2 Currently enrolling |
| Booster Vaccine for Healthy Adults (NCT04639466) | Phase 2 enrollment closed, data expected during 2025 | ||
| GEO-MVA | Mpox & smallpox | Vaccine against Mpox and smallpox (NCT TBD) | Phase 3 planning |
| Gedeptin® | Head & Neck Cancer* | ICI Combination Therapy (NCT TBD) | Phase 2 planning |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.